-
Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal
•
Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out transaction from Mitsubishi Chemical Group Corporation. The deal, led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team, values the business at approximately JPY 510 billion…
-
Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development
•
China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm Timberlyne Therapeutics, Inc., granting the startup biopharma exclusive development, manufacturing, and commercialization rights to its CM313, a CD38-targeted monoclonal antibody (mAb). The agreement covers global rights, excluding mainland China, Hong Kong, Macau, and Taiwan. Financial…
